efzimfotase alfa

all catalysts(0)

nothing on the calendar yet

News(2)

• Wainua flop narrows AstraZeneca’s path to $80B goal ahead of high-risk readouts
  With a Phase 3 failure denting the rare disease drug’s prospects, AstraZeneca has little room for error as it plots a path toward its ambitious 2030 sales target.
  biospace · 24d ago
• Ipsen’s $450M blood cancer drug; FDA selects first cohort for “pre-check” pilot program
  The planned acquisition of Kartos Therapeutics would hand Ipsen a late-stage asset for myelofibrosis. Elsewhere, Sobi hit a regulatory setback and BeOne unveiled more positive Brukinsa data.
  biopharma_dive · 1mo ago